OPRL1 and Sepsis: LY2940094 is a potent and selective NOP antagonist (Ferrari et al., 2020) currently in development for other disease indications (NCT03193398 and NCT03608371); its effects in sepsis are unknown (Witkin et al., 2016; Witkin et al., 2019).